## Core Concept
The prognosis of Acute Myeloid Leukemia (AML) is influenced by various factors, including cytogenetic abnormalities, molecular genetic mutations, age of the patient, and the presence of specific surface markers. Understanding these factors is crucial for determining the treatment outcome and survival rate of AML patients.

## Why the Correct Answer is Right
The correct answer, , is associated with a poorer prognosis in AML patients. This is because certain cytogenetic and molecular abnormalities are linked to a worse outcome. For instance, complex karyotype, mutations in FLT3 (particularly FLT3-ITD), and absence of favorable genetic markers like t(8;21) or inv(16) are known to confer a poorer prognosis.

## Why Each Wrong Option is Incorrect
* **Option A:** is generally considered a good prognostic factor in AML. This abnormality is commonly associated with the M2 subtype of AML and often responds well to treatment, especially when treated with targeted therapies.
* **Option B:** is also a good prognostic factor. Patients with this abnormality tend to have a better response to therapy and improved survival rates compared to those with adverse cytogenetic features.
* **Option C:** is associated with a relatively good prognosis, particularly when treated appropriately. This abnormality is characteristic of the M4Eo subtype of AML.

## Clinical Pearl / High-Yield Fact
A key clinical pearl for AML prognosis is the importance of cytogenetic and molecular profiling at diagnosis. For example, the presence of t(8;21) or inv(16) significantly influences treatment decisions and predicts a more favorable outcome. Conversely, complex karyotypes or FLT3-ITD mutations signal a need for more aggressive or targeted therapeutic approaches.

## Correct Answer: D.